These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 33100796)
21. Mood stabilizers during breastfeeding: a systematic review of the recent literature. Uguz F; Sharma V Bipolar Disord; 2016 Jun; 18(4):325-33. PubMed ID: 27297617 [TBL] [Abstract][Full Text] [Related]
22. [Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists: analysis of 7-year data]. Xu G; Chen E; Mao E; Che Z; He J Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Jul; 30(7):640-645. PubMed ID: 30045790 [TBL] [Abstract][Full Text] [Related]
23. Antipsychotic and antiepileptic drugs in bipolar disorder: the importance of therapeutic drug monitoring. Musenga A; Saracino MA; Sani G; Raggi MA Curr Med Chem; 2009; 16(12):1463-81. PubMed ID: 19355900 [TBL] [Abstract][Full Text] [Related]
24. A National Survey of Attitudes and Practices of Physicians Relating to Therapeutic Drug Monitoring and Clinical Pharmacokinetic Service: Strategies for Enhancing Patient's Care in Saudi Arabia. Alrabiah Z; Alwhaibi A; Alsanea S; Alanazi FK; Abou-Auda HS Int J Gen Med; 2021; 14():1513-1524. PubMed ID: 33935513 [TBL] [Abstract][Full Text] [Related]
25. Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring. Vella T; Mifsud J J Pharm Pharmacol; 2014 Jun; 66(6):747-59. PubMed ID: 24392714 [TBL] [Abstract][Full Text] [Related]
26. Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001-2004. Depp C; Ojeda VD; Mastin W; Unützer J; Gilmer TP Psychiatr Serv; 2008 Oct; 59(10):1169-74. PubMed ID: 18832503 [TBL] [Abstract][Full Text] [Related]
27. The relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. Janicak PG J Clin Psychiatry; 1993 Sep; 54 Suppl():35-41; discussion 55-6. PubMed ID: 8104932 [TBL] [Abstract][Full Text] [Related]
28. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. Namjoshi MA; Risser R; Shi L; Tohen M; Breier A J Affect Disord; 2004 Sep; 81(3):223-9. PubMed ID: 15337326 [TBL] [Abstract][Full Text] [Related]
29. Evaluating appropriateness of digoxin, carbamazepine, valproic acid, and phenytoin usage by therapeutic drug monitoring. Dalaklioglu S Clin Lab; 2013; 59(3-4):325-31. PubMed ID: 23724621 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. Fajutrao L; Paulsson B; Liu S; Locklear J Clin Ther; 2009 Jun; 31 Pt 1():1456-68. PubMed ID: 19698903 [TBL] [Abstract][Full Text] [Related]
31. Sexual Dysfunction and Mood Stabilizers in Long-Term Stable Patients With Bipolar Disorder. García-Blanco A; García-Portilla MP; Fuente-Tomás L; Batalla M; Sánchez-Autet M; Arranz B; Safont G; Arqués S; Livianos L; Sierra P J Sex Med; 2020 May; 17(5):930-940. PubMed ID: 32139195 [TBL] [Abstract][Full Text] [Related]
32. Understanding the molecular mechanisms underlying mood stabilizer treatments in bipolar disorder: Potential involvement of epigenetics. Pisanu C; Papadima EM; Del Zompo M; Squassina A Neurosci Lett; 2018 Mar; 669():24-31. PubMed ID: 27343410 [TBL] [Abstract][Full Text] [Related]
33. Benefits and Limits of Antiretroviral Drug Monitoring in Routine Practice. Maitre T; Muret P; Blot M; Waldner A; Duong M; Si-Mohammed A; Chavanet P; Aho S; Piroth L Curr HIV Res; 2019; 17(3):190-197. PubMed ID: 31490758 [TBL] [Abstract][Full Text] [Related]
34. Impact of a pharmacist-led mood stabilizer laboratory monitoring protocol. Horvath K; Scott M J Am Pharm Assoc (2003); 2022; 62(6):1870-1874. PubMed ID: 35842299 [TBL] [Abstract][Full Text] [Related]
35. [Therapeutic management of bipolar disorder in France and Europe: a multinational longitudinal study (WAVE-bd)]. Bellivier F; Delavest M; Coulomb S; Figueira ML; Langosch JM; Souery D; Vieta E Encephale; 2014 Oct; 40(5):392-400. PubMed ID: 25238903 [TBL] [Abstract][Full Text] [Related]
37. Monitoring Protein-Unbound Valproic Acid Serum Concentrations in Clinical Practice. Wallenburg E; Klok B; de Jong K; de Maat M; van Erp N; Stalpers-Konijnenburg S; Essink G; van Luin M Ther Drug Monit; 2017 Jun; 39(3):269-272. PubMed ID: 28437285 [TBL] [Abstract][Full Text] [Related]
39. Challenges in comparing treatment outcome from a prospective with that of a retrospective study: assessing the merit of gentamicin therapeutic drug monitoring in pediatric oncology. Ho KK; Thiessen JJ; Bryson SM; Greenberg ML; Einarson TR; Leson CL Ther Drug Monit; 1994 Jun; 16(3):238-47. PubMed ID: 8085278 [TBL] [Abstract][Full Text] [Related]
40. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. Schoretsanitis G; Paulzen M; Unterecker S; Schwarz M; Conca A; Zernig G; Gründer G; Haen E; Baumann P; Bergemann N; Clement HW; Domschke K; Eckermann G; Egberts K; Gerlach M; Greiner C; Havemann-Reinecke U; Hefner G; Helmer R; Janssen G; Jaquenoud-Sirot E; Laux G; Messer T; Mössner R; Müller MJ; Pfuhlmann B; Riederer P; Saria A; Schoppek B; Silva Gracia M; Stegmann B; Steimer W; Stingl JC; Uhr M; Ulrich S; Waschgler R; Zurek G; Hiemke C World J Biol Psychiatry; 2018 Apr; 19(3):162-174. PubMed ID: 29493375 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]